IVI Leadership Invited to Speak at the 2018 BIO International Convention

2018-06-15T12:16:55+00:00June 4th, 2018|Events, IVI News|

The 2018 BIO International Convention will be held in Boston, MA from June 4th through June 7th. IVI’s Jennifer Bright (Acting Executive Director) and Mark Linthicum (Director of Scientific Communications) are among the speakers invited to the 2018 BIO International Convention, where they will be discussing value assessment frameworks and patient value. The description of each session is provided below, along with a link to the corresponding BIO International Convention webpage where you can find additional information.

Orphan and Rare Disease Track Opening Remarks and Session: Patient Value in HTA and Access Decisions

Date: Tuesday, June 5, 2018
Time: 11:00 AM – 12:15 PM EDT
Session ID: 45181

IVI Speaker: Mark Linthicum, Director of Scientific Communications

Defining and differentiating value in rare disease space is critical to ensuring access to patients. How should decisions around access and coverage be guided by value to patients? What is needed to maintain an innovative environment and investments that produce value for patients while also considering stakeholder concerns around cost? Join a robust discussion with experts who will discuss new and innovative approaches to value in the healthcare system while ensuring access to patients.

LEARN MORE




New Role for Value Assessment Frameworks in the U.S.

Date: Wednesday, June 6, 2018
Time: 1:45 PM – 2:45 PM EDT
Session ID: 419181

IVI Speaker: Jennifer Bright, Acting Executive Director

Across the healthcare system as stakeholders look to better account for value, different value assessment frameworks are emerging. These frameworks take different approaches but ultimately have the same goal – to quantify and define the value of medicine. With so many different value assessment frameworks, how do we find common ground in the approach to measuring value and accounting for what value means to patients. Panelists will discuss the current landscape of value assessment frameworks, how they are evolving, and what this means for patients’ access to medicines.

LEARN MORE